We provide our members with support to do cutting-edge research through:
- Introductions to collaborators from our home institutions and the wider network of HIV leading investigators
- Identifying opportunities for funding through NIH or other funding bodies
- Providing strategies for competitive grant applications and feedback from senior investigators on grant drafts
- Assistance with organizing multi-investigator grant submissions
For funding opportunities visit the following sites:
Featured Funding Opportunities
NIDA seeks early career investigators
PAS-21-270: AIDS-Science Track Award for Research Transition (A-START) (R03 Clinical Trial Optional)—Applications due Jan. 7, 2022
This funding opportunity announcement (FOA) seeks to facilitate the entry of both newly independent and early career investigators to the area of drug use and use disorder research and HIV/AIDS. This FOA, the AIDS-Science Track Award for Research Transition (A-START), encourages Small Research Grant (R03) applications to support research projects on drug use and/or use disorder and HIV/AIDS that can be carried out in a short period of time with limited resources. This FOA welcomes applications integrating substance use and/or substance use disorder and HIV/AIDS across all areas of research supported by NIDA.
Use existing data to promote substance use research
PAR-19-368: Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)—Applications due Jan. 7, 2022
The purpose of this funding opportunity announcement (FOA) is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance-using behaviors (substances defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology; trajectories of substance-using behaviors and their consequences including morbidity and mortality; risk and resilience in the development of psychopathology; and strategies to guide the development, testing, implementation, and delivery of high-quality, effective, and efficient services for the prevention and treatment of substance use disorder and HIV.
Support for research into HIV-associated neurological disorders (HAND)
RFA-DA-22-009: Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional)—Applications due Nov. 17, 2021
This funding opportunity announcement invites grant applications to study mechanisms underlying the neuropathophysiology of HIV-associated neurological disorders (HAND) using induced microglia and cerebral organoids generated from human-derived induced pluripotent stem cell lines. Specific emphasis is on the comorbidity of HIV and neural stimulants, including methamphetamine, amphetamine, cocaine, and nicotine, studied at the single cell and neural circuits levels.
Other Recent Funding Opportunities
- NOT-DA-21-020: Notice of Special Interest (NOSI): Evaluation of sex differences on HIV-associated comorbidities in the context of stimulant use—Applications due Jan. 7, 2022
- NOT-DA-21-007: Notice of Special Interest (NOSI): Using Data to Advance HIV Epidemic Knowledge and Program Planning—Applications due Jan. 7, 2022
- PA-21-205: Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)—Applications due Jan. 7, 2022
- PAR-20-147: Extracellular RNA carrier subclasses in processes relevant to substance use disorders or HIV infection (R01- Clinical Trial Not Allowed)—Applications due Jan. 7, 2022
- PAR-22-027: Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)—Applications due Jan. 11, 2022
- NOT-DA-21-074: Notice of NIDA's Participation in RFA-AI-20-076, "New Technologies for the In vivo Delivery of Gene Therapeutics for an HIV Cure (R01 Clinical Trial Not Allowed)"—Applications due March 17, 2022